Sugi Predict

Sugi Predict / Compounds / SCHEMBL12933259

SCHEMBL12933259

SCHEMBL12933259

O=C(NO)c1ccc(N2CCOC(CNS(=O)(=O)c3ccc4ccccc4c3)C2)nc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HDAC3 O15379 12/20 0.51
▸ HDAC4 P56524 12/20 0.51
▸ HDAC1 Q13547 12/20 0.51
▸ HDAC7 Q8WUI4 12/20 0.51
▸ HDAC2 Q92769 12/20 0.51
▸ HDAC10 Q969S8 12/20 0.51
▸ HDAC11 Q96DB2 12/20 0.51
▸ HDAC8 Q9BY41 12/20 0.51
▸ HDAC6 Q9UBN7 12/20 0.51
▸ HDAC9 Q9UKV0 12/20 0.51
▸ HDAC5 Q9UQL6 12/20 0.51
▸ CYP2D6 P10635 2/20 0.51
▸ CYP3A4 P08684 1/20 0.51
▸ CYP2C19 P33261 1/20 0.51
▸ LMNA P02545 3/20 0.50
▸ F10 P00742 1/20 0.43
▸ ALDH1A1 P00352 3/20 0.42
▸ HPGD P15428 2/20 0.42
▸ SMN1; SMN2 Q16637 2/20 0.42
▸ NPC1 O15118 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13538744 0.90 HDAC6 (0.61) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL12933256 0.88 HDAC6 (0.47) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL13538785 0.87 LMNA (0.47) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL10194453 0.84 HDAC1 (0.56) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL10194633 0.79 HDAC3 (0.60) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL13538784 0.79 LMNA (0.48) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL12933253 0.78 HDAC6 (0.58) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL12933255 0.78 HDAC6 (0.58) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL10194627 0.77 HDAC8 (0.59) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL12933263 0.76 HDAC6 (0.60) HDAC3HDAC4HDAC1HDAC7HDAC2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210060014-A1 COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS CERENO SCIENTIFIC AB (SE) 2021-03-04 — — US disclosed
US-20170020874-A1 COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS CERENO SCIENT AB (SE) 2017-01-26 — — US disclosed
US-20140051716-A1 COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS CERENO SCIENTIFIC AB 2014-02-20 — — US disclosed
US-20140051716-A1 COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS CERENO SCIENTIFIC AB 2014-02-20 — — US disclosed
US-8501737-B2 Piperazinyl-, piperidinyl- and morpholinyl-derivatives as novel inhibitors of histone deacetylase JANSSEN PHARMACEUTICA N.V. (BE) 2013-08-06 — — US disclosed
US-8501737-B2 Piperazinyl-, piperidinyl- and morpholinyl-derivatives as novel inhibitors of histone deacetylase JANSSEN PHARMACEUTICA N.V. (BE) 2013-08-06 — — US disclosed
US-7868205-B2 Inhibitors of histone deacetylase METHYLGENE INC. (CA) 2011-01-11 — — US disclosed
US-7868205-B2 Inhibitors of histone deacetylase METHYLGENE INC. (CA) 2011-01-11 — — US disclosed
US-20100009988-A1 PIPERAZINYL-, PIPERIDINYL- AND MORPHOLINYL-DERIVATIVES AS NOVEL INHIBITORS OF HISTONE DEACETYLASE EMELEN KRISTOF VAN 2010-01-14 — — US disclosed
US-20100009988-A1 PIPERAZINYL-, PIPERIDINYL- AND MORPHOLINYL-DERIVATIVES AS NOVEL INHIBITORS OF HISTONE DEACETYLASE EMELEN KRISTOF VAN 2010-01-14 — — US disclosed
US-7592450-B2 used to inhibit proliferative conditions, such as cancer and psoriasis, with improved bioavailability and stability JANSSEN PHARMACEUTICA N.V. (BE) 2009-09-22 — — US disclosed
US-7592450-B2 used to inhibit proliferative conditions, such as cancer and psoriasis, with improved bioavailability and stability JANSSEN PHARMACEUTICA N.V. (BE) 2009-09-22 — — US disclosed
US-20080132459-A1 Inhibitors of Histone Deacetylase METHYLGENE, INC. (CA) 2008-06-05 — — US disclosed
US-20080132459-A1 Inhibitors of Histone Deacetylase METHYLGENE, INC. (CA) 2008-06-05 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140051716-A1 COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS HDAC3, HDAC1, HDAC2 HDAC3 1/4885HDAC4 7/4885HDAC1 2/4885
US-20170020874-A1 COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS HDAC3, HDAC1, HDAC2 HDAC3 1/4885HDAC4 7/4885HDAC1 2/4885
US-20080132459-A1 Inhibitors of Histone Deacetylase HDAC1, HDAC5, HDAC3 HDAC3 3/4885HDAC4 8/4885HDAC1 1/4885
US-20100009988-A1 PIPERAZINYL-, PIPERIDINYL- AND MORPHOLINYL-DERIVATIVES AS NOVEL INHIBITORS OF HISTONE DEACETYLASE HDAC1, HDAC2, HDAC5 HDAC3 4/4885HDAC4 11/4885HDAC1 1/4885
US-20210060014-A1 COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS HDAC3, HDAC1, HDAC2 HDAC3 1/4885HDAC4 7/4885HDAC1 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback